Menu
Menu
In this short interview, Arantxa Hervás, CGT Dx Director at Vitrolife Group, shares why her lab moved from a multi-test NGS model to the SOPHiA DDM™ Enhanced Clinical Exome Solution, and what has changed for them since.
For Gorka Alkorta-Aranburu, Head of the Genetics and Genomics Diagnostic Laboratory at Clínica Universidad de Navarra, the move to whole genome sequencing (WGS) was a deliberate leap, not a gradual one.
Read our latest user spotlight, featuring Dr. Hemad Yasaei, Head of Molecular Genomics at the National Reference Laboratory (M42) in Abu Dhabi.
Explore how Dasa and SOPHiA GENETICS are collaborating to advance precision oncology research and drive real-world impact.
In this user spotlight, we had the pleasure of interviewing Dr. Robert Akkers, Molecular Biologist at Result Laboratorium, one of our valued and long-standing partners in the Netherlands.
Discover how Dr. Christophe Marzac and his team at Gustave Roussy use the SOPHiA DDM™ Platform to streamline high‑volume genomic workflows, ensure stable variant interpretation, and provide important insights to support hematologic cancer research.
How an NHS England genomics laboratory is streamlining hereditary cancer analysis with SOPHiA DDM™
Discover how precision genomics research at Hospital de Amor, Brazil, uncovered a rare gene fusion in a pediatric glioma, providing valuable insights to support a young patient's health journey.
Prof. Barbara Izzo and her team at CEINGE – Biotecnologie Avanzate opened the doors of their laboratory to discuss the growing importance of integrated molecular approaches in the diagnosis of acute myeloid leukemia (AML).
Hear Dr. Gilles Millat speak about the expansion of cardiogenetic testing and how the SOPHiA DDM™ Cardio Peer Network strengthens variant classification workflows.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.